APA (7th ed.) Citation

P, P., M, B., E, G., R, S., L, B., L, P., . . . E, B. (2024). SGLT2-inhibitors in diabetic patients with severe aortic stenosis and cardiac damage undergoing transcatheter aortic valve implantation (TAVI). Cardiovascular diabetology, 23(1), 420. https://doi.org/10.1186/s12933-024-02504-8

Chicago Style (17th ed.) Citation

P, Paolisso, et al. "SGLT2-inhibitors in Diabetic Patients with Severe Aortic Stenosis and Cardiac Damage Undergoing Transcatheter Aortic Valve Implantation (TAVI)." Cardiovascular Diabetology 23, no. 1 (2024): 420. https://doi.org/10.1186/s12933-024-02504-8.

MLA (9th ed.) Citation

P, Paolisso, et al. "SGLT2-inhibitors in Diabetic Patients with Severe Aortic Stenosis and Cardiac Damage Undergoing Transcatheter Aortic Valve Implantation (TAVI)." Cardiovascular Diabetology, vol. 23, no. 1, 2024, p. 420, https://doi.org/10.1186/s12933-024-02504-8.